Aduro Biotech

Aduro Biotech is an immunotherapy company focused on the discovery, development and commercialization of therapies for treament of diseases, including cancer. Product candidates from the company's STING Pathway Activator, B-select monoclonal antibody, and Live, Attenuated, Double-Deleted Listeria monocytogenes platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies as well as other immunotherapies. The company's STING Pathway technology platform include its main molecule ADU-S100, which targets STING. The company is also in preclinical development of a CTLA-4 checkpoint inhibitor blocking antibody.
  • TickerADRO
  • ISINUS00739L1017
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ResearchPool Subscriptions

Get the most out of your insights

Get in touch